CATALYST BIOSCIENCES RAISES $30 MILLION SERIES B FINANCING

Catalyst Biosciences, Inc.,a privately held biotechnology company focused on engineering and developing novel therapeutic protease products, today announced it has raised $30 million in its Series B financing. The investment was led by Morgenthaler Ventures. Also participating in the financing was HealthCare Ventures and all of Catalyst's previous investors, including Sofinnova Ventures, Burrill & Company, RCT BioVentures and Novartis Venture Fund.
American Venture Magazine